[HTML][HTML] Survival with axicabtagene ciloleucel in large B-cell lymphoma
JR Westin, OO Oluwole, MJ Kersten… - … England Journal of …, 2023 - Mass Medical Soc
Background In an analysis of the primary outcome of this phase 3 trial, patients with early
relapsed or refractory large B-cell lymphoma who received axicabtagene ciloleucel (axi-cel) …
relapsed or refractory large B-cell lymphoma who received axicabtagene ciloleucel (axi-cel) …
Updates on CAR T‐cell therapy in B‐cell malignancies
By increasing disease‐free survival and offering the potential for long‐term cure, chimeric
antigen receptor (CAR) T‐cell therapy has dramatically expanded therapeutic options …
antigen receptor (CAR) T‐cell therapy has dramatically expanded therapeutic options …
Infectious complications of CAR T-cell therapy across novel antigen targets in the first 30 days
L Mikkilineni, B Yates, SM Steinberg… - Blood …, 2021 - ashpublications.org
Infections are a known complication of chimeric antigen receptor (CAR) T-cell therapy with
data largely emerging from CD19 CAR T-cell targeting. As CAR T-cell therapy continues to …
data largely emerging from CD19 CAR T-cell targeting. As CAR T-cell therapy continues to …
CD19/22 CAR T cells in children and young adults with B-ALL: phase 1 results and development of a novel bicistronic CAR
H Shalabi, H Qin, A Su, B Yates… - Blood, The Journal …, 2022 - ashpublications.org
Remission durability following single-antigen targeted chimeric antigen receptor (CAR) T-
cells is limited by antigen modulation, which may be overcome with combinatorial targeting …
cells is limited by antigen modulation, which may be overcome with combinatorial targeting …
[HTML][HTML] Deep immune profiling reveals targetable mechanisms of immune evasion in immune checkpoint inhibitor-refractory glioblastoma
EF Simonds, ED Lu, O Badillo, S Karimi… - … for immunotherapy of …, 2021 - ncbi.nlm.nih.gov
Background Glioblastoma (GBM) is refractory to immune checkpoint inhibitor (ICI) therapy.
We sought to determine to what extent this immune evasion is due to intrinsic properties of …
We sought to determine to what extent this immune evasion is due to intrinsic properties of …
[HTML][HTML] Diagnostic approach to the evaluation of myeloid malignancies following CAR T-cell therapy in B-cell acute lymphoblastic leukemia
G Mo, HW Wang, AC Talleur, SA Shahani… - … for immunotherapy of …, 2020 - ncbi.nlm.nih.gov
Immunotherapeutic strategies targeting B-cell acute lymphoblastic leukemia (B-ALL)
effectively induce remission; however, disease recurrence remains a challenge. Due to the …
effectively induce remission; however, disease recurrence remains a challenge. Due to the …
[HTML][HTML] Landscape of germline cancer predisposition mutations testing and management in pediatrics: Implications for research and clinical care
SA Shahani, EL Marcotte - Frontiers in pediatrics, 2022 - frontiersin.org
As germline genetic testing capacities have improved over the last two decades,
increasingly more people are newly diagnosed with germline cancer susceptibility …
increasingly more people are newly diagnosed with germline cancer susceptibility …
Benefit of axicabtagene ciloleucel versus chemoimmunotherapy in older patients and/or patients with poor ECOG performance status with relapsed or refractory large …
Axicabtagene ciloleucel (axi‐cel) in trials has demonstrated favorable efficacy compared
with historical controls after≥ 2 lines of therapy for the treatment of relapsed or refractory …
with historical controls after≥ 2 lines of therapy for the treatment of relapsed or refractory …
Attention deficit hyperactivity disorder screening electrocardiograms: a community-based perspective
SA Shahani, WN Evans, GA Mayman, VC Thomas - Pediatric cardiology, 2014 - Springer
Screening electrocardiograms (EKGs) for attention deficit hyperactivity disorder (ADHD)
medication administration is controversial. We reviewed our experience as a community …
medication administration is controversial. We reviewed our experience as a community …
Improved Overall Survival with Axicabtagene Ciloleucel Vs Standard of Care in Second-Line Large B-Cell Lymphoma Among the Elderly: A Subgroup Analysis of …
Introduction: Historically, older patients (pts) with relapsed/refractory large B-cell lymphoma
(R/R LBCL) were often deemed ineligible for curative-intent autologous stem cell transplant …
(R/R LBCL) were often deemed ineligible for curative-intent autologous stem cell transplant …